Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
René RettlTim WollenweberFranz DucaChristina BinderBernhard CherounyTheresa-Marie DachsCamuz Ligios LucianaLore SchrutkaDaniel DalosDietrich BeiztkeChristian LoeweRoza Badr EslamJohannes KastnerMarcus HackerChristina Binder-RodriguezPublished in: European heart journal. Cardiovascular Imaging (2023)
99mTc-DPD SPECT/CT imaging with determination of SUV retention index as part of a routine annual examination can provide evidence of treatment response in ATTR-CM patients receiving disease-modifying therapy. Further long-term studies with 99mTc-DPD SPECT/CT imaging may help to evaluate the relationship between tafamidis-induced reduction in SUV retention index and outcome in patients with ATTR-CM and will demonstrate whether highly disease-specific 99mTc-DPD SPECT/CT imaging is more sensitive than routine diagnostic monitoring.